In particular, murine tumor models treated with viruses engineered to enhance CD8 T cell responses against major histocompatibility complex (MHC) class I-restricted, tumor-specific epitopes have resulted in reduced tumor burden [3,5]. This evidence concerns the gene CD8A and neoplasm.